

Freedom of Information Request	FOI 23-609	8 th December 2023
--------------------------------	------------	-------------------------------

Your request

You requested the following:

Q1. How many patients were treated in October 2023 (or latest available month) by the Dermatology department with the following drugs:

Abrocitinib (Cibinqo)
Baricitinib (Olumiant)
Dupilumab (Dupixent)
Omalizumab (Xolair)
Tralokinumab (Adtralza)
Upadacitinib (Rinvoq)

Q2. How many patients were treated in October 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:

Benralizumab (Fasenra)
Dupilumab (Dupixent)
Mepolizumab (Nucala)
Omalizumab (Xolair)
Reslizumab (Cinqaero)
Tezepelumab (Tezspire)

Our response

For questions 1 and 2, we are not able to provide information on the treatment drugs prescribed to individual patients for all medical conditions as it is not recorded centrally. To comply with your request, we would need to review every patient record which we have established would take in excess of 18 hours to undertake and therefore exceeds the appropriate costs limit under Section 12 of the Freedom of Information Act 2000, which is currently £450. This is not an exemption which requires us to consider the application of the public interest test.